Neogenomics EV/EBIT NEO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 234×; Apr 2020
10-year median: 199×
10-year range: 71.1× to 323×
Peer median: 15.5×

Neogenomics has no meaningful EV/EBIT today: it made an operating loss of $68.4M over the last twelve months.

It was last meaningful in Apr 2020, at 234×.

On the days it had one over the last ten years, its median was 199×, from 71.1× in Apr 2017 to 323× in Nov 2018.

EV/EBIT over time

median 199.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	234×	190×	259×
2019	225×	106×	250×
2018	103×	96.9×	323×
2017	250×	71.1×	258×
2016	433×	336×	434×
2015	490×	96.8×	497×
2014	105×	44.5×	124×
2013	80.5×	76.9×	444×
2012	78.6×	48.9×	91.3×

Against its peers

Companies in Specialty Business Services nearest Neogenomics' size, closest first, today.

Company	EV/EBIT
NEONeogenomics	n/m
VVXV2X	15.5×
MHMcGraw Hill	15.4×
DFINDonnelley Financial Solutions	10.5×
CRAICRA International	18.0×
ITGartner	12.7×
ULSUL Solutions	24.6×
Peer median	15.5×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Neogenomics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.